Carcinoma, Non-Small-Cell Lung — Expanded Access Programs
Overview
Right2Hope maintains a directory of 61 expanded access programs, clinical trials, and compassionate use pathways listed for Carcinoma, Non-Small-Cell Lung. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with carcinoma, non-small-cell lung programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 23 programs are currently active or recruiting, with the remaining 38 in other lifecycle stages. Sponsors actively running programs in this area include Janssen Research & Development, LLC, Merck Sharp & Dohme LLC, AstraZeneca, Eli Lilly and Company, Pfizer, and others.
By recruiting status
Snapshot of where every Carcinoma, Non-Small-Cell Lung program currently sits in its lifecycle.
- Active / Recruiting23
- Inactive38
Top sponsors
Organisations running the most Carcinoma, Non-Small-Cell Lung programs in the directory.
- Janssen Research & Development, LLC10 programs
- Merck Sharp & Dohme LLC6 programs
- AstraZeneca4 programs
- Eli Lilly and Company4 programs
- Pfizer4 programs
- Bristol-Myers Squibb3 programs
- Novartis Pharmaceuticals3 programs
- Seagen Inc.3 programs
- Andarix Pharmaceuticals1 program
- BerGenBio ASA1 program
Carcinoma, Non-Small-Cell Lung programs (61)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Global Study on Rilvegostomig or Pembrolizumab for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — AstraZeneca
- Study Comparing Alectinib with Platinum-Based Chemotherapy for ALK Positive Non-Small Cell Lung Cancer — Hoffmann-La Roche
- Study on Adagrasib, Pembrolizumab, and Chemotherapy vs. Placebo, Pembrolizumab, and Chemotherapy for Untreated Non-Squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation — Mirati Therapeutics Inc.
- Study on Amivantamab and Capmatinib Combination Therapy for Advanced Non-Small Cell Lung Cancer — Janssen Research & Development, LLC
- Study on Amivantamab and Lazertinib with Chemotherapy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure — Janssen Research & Development, LLC
- Study on Amivantamab and Olomorasib Combination Therapy for Metastatic Non-Small Cell Lung Cancer — Janssen Research & Development, LLC
- Study on BMS-986504 for Advanced or Metastatic Non-small Cell Lung Cancer with Specific Genetic Deletion — Bristol-Myers Squibb
- Study Comparing Amivantamab with Chemotherapy to Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions — Janssen Research & Development, LLC
- Study of DM005 for Patients with Advanced Solid Tumors — Doma Biopharmaceutical（Suzhou）Co., Ltd.
- Study of New Treatments for Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study Comparing Lorlatinib and Crizotinib for First-Time Treatment in ALK-Positive Lung Cancer Patients — Pfizer
- Study on TAK-788 for Adults with Non-Small Cell Lung Cancer — Takeda
- Study on PF-08634404 with Chemotherapy for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer — Pfizer
- Study on Pembrolizumab with or without Chemotherapy for Stage IV Non-small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study on MK-3475 and Gemcitabine for Treating Advanced Non-Small Cell Lung Cancer (NSCLC) — Providence Health & Services
- Study on JDQ443 Combination Therapy for Advanced Solid Tumors with KRAS G12C Mutation — Novartis Pharmaceuticals
- Study on Reducing Infusion Reactions with Premedication Before Amivantamab Treatment — Janssen Research & Development, LLC
- Study on Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in Non-Small Cell Lung Cancer (NSCLC) — Weill Medical College of Cornell University
- Study on Olomorasib with Standard Treatment for Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Eli Lilly and Company
- Study on Pembrolizumab with Chemoradiation Therapy, Followed by Pembrolizumab with or without Olaparib, for Stage III Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study on PF-08634404 with Other Cancer Medicines for Advanced Cancers — Pfizer
- Study on THIO and Cemiplimab for Advanced Non-Small Cell Lung Cancer (NSCLC) — Maia Biotechnology
- Study on How the Combination of Sigvotatug Vedotin and Pembrolizumab Works in People with Non-Small Cell Lung Cancer with High PD-L1 Levels — Pfizer
- Study on the Safety and Effectiveness of Bemcentinib with Pembrolizumab, Pemetrexed, and Carboplatin for Untreated Non-squamous Non-small Cell Lung Cancer — BerGenBio ASA
- Phase 2 Study of Adding Vitamin C to Chemotherapy and Radiation for Non-Small Cell Lung Cancer — Joseph J. Cullen, MD, FACS
- Study on Amivantamab with Lazertinib or Chemotherapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer — Janssen Research & Development, LLC
- Study on Amivantamab for Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer — Janssen Research & Development, LLC
- A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer — Janssen Research & Development, LLC
- Study on Combination Therapy with Amivantamab and Docetaxel for Metastatic Non-Small Cell Lung Cancer — Janssen Research & Development, LLC
- Study on Disitamab Vedotin for Previously Treated Solid Tumors with HER2 Marker — Seagen Inc.
- Study on LY3537982 with Immunotherapy and Possibly Chemotherapy for Non-Small Cell Lung Cancer with KRAS G12C Mutation — Eli Lilly and Company
- A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer — Forward Pharmaceuticals Co., Ltd.
- Study on JNJ-90301900 with Chemoradiation and Immunotherapy for Non-Small Cell Lung Cancer — Johnson & Johnson Enterprise Innovation Inc.
- Study of LP-300 with Carboplatin and Pemetrexed in Non-Smokers with Advanced Lung Cancer — Lantern Pharma Inc.
- Study on MORAb-202 for Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer Adenocarcinoma — Bristol-Myers Squibb
- Study on Pembrolizumab With or Without V940 for Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study Comparing Repotrectinib and Crizotinib for Advanced ROS1-positive Non-Small Cell Lung Cancer — Bristol-Myers Squibb
- Study on Selpercatinib After Surgery or Radiation for Non-Small Cell Lung Cancer (NSCLC) — Eli Lilly and Company
- A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01). — Seagen Inc.
- Study on the Safety and Effectiveness of AZD7789 in Adults with Advanced or Metastatic Solid Cancer — AstraZeneca
- Study on Durvalumab and Tremelimumab with Chemotherapy Compared to Pembrolizumab with Chemotherapy for Metastatic Non-Small Cell Lung Cancer — AstraZeneca
- Afatinib Expanded Access Program — Boehringer Ingelheim
- Expanded Access to Mobocertinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon20 Insertion Mutations — Millennium Pharmaceuticals, Inc.
- Astra Zeneca ISABR Study: Testing Radiation and Immunotherapy for Early-Stage Lung Cancer — Jonsson Comprehensive Cancer Center
- Study on Genetically Modified Immune Cells for Treating Advanced Non-Small Cell Lung Cancer — Intima Bioscience, Inc.
- Study on Durvalumab and Tremelimumab with Chemotherapy for Virus-Infected Patients with Advanced Non-Small Cell Lung Cancer — Georgetown University
- Study on Durvalumab vs Placebo with Radiation Therapy in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients and Osimertinib After Radiation in Patients with EGFR Mutation — AstraZeneca
- Study on the Effectiveness and Safety of Tisotumab Vedotin for Patients with Solid Tumors — Seagen Inc.
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib — Janssen Research & Development, LLC
- Study on Using Immune Profile to Guide Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Immunotherapy — Hackensack Meridian Health
- Study on Inhaled Azacytidine with Chemotherapy and Immunotherapy for Treating Early-Stage Non-Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on NT-I7 and Atezolizumab for Untreated Advanced or Metastatic Lung Cancer with PD-L1 Expression — NeoImmuneTech
- Study on Osimertinib for Treating Lung Cancer with EGFR Mutation — Dana-Farber Cancer Institute
- Study on Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib for Advanced Lung Cancer Patients Who Progressed on Osimertinib — Genprex, Inc.
- Study on Rhenium Re 188 P2045 for Lung Cancer Patients Who Have Had or Refused Chemotherapy — Andarix Pharmaceuticals
- Study on the Safety and Effectiveness of Radiation Therapy Combined with Durvalumab for Treating Residual Lung Cancer — University of Nebraska
- Study on JDQ443 for Patients with Advanced Solid Tumors with KRAS G12C Mutation — Novartis Pharmaceuticals
- Study on LY3537982 for Cancer Patients with a Specific Genetic Mutation (KRAS G12C) — Eli Lilly and Company
- Study Comparing Pembrolizumab Alone Versus Pembrolizumab with Sacituzumab Govitecan for Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels — Merck Sharp & Dohme LLC
- Study on Pembrolizumab/Vibostolimab with Chemoradiotherapy Compared to Durvalumab for Stage III Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Access to Capmatinib for Treating MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) — Novartis Pharmaceuticals
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Carcinoma, Non-Small-Cell Lung to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.